课题基金 / 基金详情

POLY (ADP-RIBOSE) SYNTHETASE AND REPERFUSION INJURY

POLY (ADP-RIBOSE) SYNTHETASE AND REPERFUSION INJURY
聚(ADP-核糖)合成酶和再灌注损伤
批准号:
2857941
负责人:
CSABA SZABO
金额:
$20.31万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-01-01 至 2000-12-31

项目摘要

项目成果

CSABA SZABO的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (adapted from the applicant's abstract): The current proposal is aimed at investigating the role of the nuclear enzyme poly (ADP-ribose) synthetase (PARS) in the pathophysiology of myocardial ischemia-reperfusion injury. First, it will be established whether pharmacological inhibition of PARS ameliorates the cellular energetic derangement and the functional alterations during myocardial ischemia-reperfusion injury. This hypothesis will be tested in in vitro perfused heart preparations and in a mouse model of myocardial ischemia-reperfusion injury by correlating DNA strand-breakage, PARS activity, intracellular energetics, and myocardial contractility. PARS will be inhibited by pharmacological and molecular biological approaches. For the pharmacological approach, 3-aminobenzamide, a prototypical inhibitor of PARS will be used. Moreover, responses will be compared in hearts of wild-type mice and of knock-out mice lacking the functional PARS enzyme. The relative contribution of hydroxyl radical versus peroxynitrite in the activation of PARS in myocardial ischemia-reperfusion will also be addressed using pharmacological inhibitors. The principal investigator will also investigate the changes in endothelial function during myocardial reperfusion injury, and the role of PARS in these changes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Aminooxyacetic Acid Prodrugs for Colon Cancer Therapy
  • 批准号:
    9251701
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2017
  • 负责人:
    CSABA SZABO
  • 依托单位:
Inhibition of Bacterial and Host-Derived H2S Production for the Therapeutic Enhancement of Anti-Bacterial Host Defense
Regulation of cellular bioenergetics by hydrogen sulfide
Poly(ADP-ribose) synthetase inhibition and diabetes
海外基金